The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL

Real-world evidence of venetoclax vs ibrutinib vs idelalisibПодробнее

Treating CLL after venetoclax or BTK inhibitorsПодробнее

Venetoclax based combination therapy in AML: a real-world retrospective analysisПодробнее

Treatment options for patients with CLL after failure of covalent BTK inhibitors and venetoclaxПодробнее

Real-world treatment patterns and comparative effectiveness of BTKi in patients with MCLПодробнее

Comparison of venetoclax-based versus non-venetoclax-based treatment regimens in AMLПодробнее

Treatment Options for CLL after Bruton’s Tyrosine Kinase Inhibitor and Venetoclax (BCL2i) - ASH 2021Подробнее

Retrospective multicenter analysis of venetoclax-treated CLL patientsПодробнее

Treating patients with CLL who progress after BTK inhibitor therapyПодробнее

Finite therapies with the combination of BTKis and venetoclax in CLLПодробнее

Genomic factors influencing patient response to venetoclax-based regimens: analysis from CLL13/GAIAПодробнее

Outcomes for CLL Patients Treated with BTK inhibitor and BCL2 inhibitor - ASH 2021Подробнее

Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLLПодробнее

The real-world comparative effectiveness of covalent BTKis in R/R MCLПодробнее

A retrospective study of venetoclax re-treatment in CLL patientsПодробнее

The potential of triplet regimens combining BTKis with venetoclax and obinutuzumab in CLLПодробнее

Insights into the BRUIN CLL-322 trialПодробнее

ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patientsПодробнее

BTK Inhibition in CLL: Real-World DataПодробнее